CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 2, 2017--
Seres Therapeutics Inc., (NASDAQ:MCRB), a leading microbiome
therapeutics platform company, today announced it will present at the
Cowen and Company 37th Annual Health Care Conference in
Boston, MA on Wednesday, March 8 at 11:20 a.m. ET.
Live audio webcast of the presentation be available under the “Investors
and Media” section of Seres’ website. A replay of the presentation will
become available approximately one hour after the event and will be
archived for 21 days.
About Seres Therapeutics
Seres Therapeutics, Inc. is a
leading microbiome therapeutics platform company developing a novel
class of biological drugs that are designed to treat disease by
restoring the function of a dysbiotic microbiome, where the natural
state of bacterial diversity and function is imbalanced. The Phase 2
study of Seres' program SER-109 has been completed in multiply recurrent C.
difficile infection. Seres' second clinical candidate, SER-287,
is being evaluated in a Phase 1b study in patients with mild-to-moderate
ulcerative colitis (UC). Seres is also developing SER-262, the first
ever synthetic microbiome therapeutic candidate, in a Phase 1b study in
patients with primary C. difficile infection. For more
information, please visit www.serestherapeutics.com.
Follow us on Twitter @SeresTx.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170302005208/en/
Source: Seres Therapeutics Inc.
IR or PR Contact:
Seres
Therapeutics
Carlo Tanzi, Ph.D., 617-203-3467
Head of Investor
Relations and Corporate Communications
Ctanzi@serestherapeutics.com
